Free Trial
NASDAQ:SLGL

Sol-Gel Technologies Q3 2026 Earnings Results & Report

Sol-Gel Technologies logo
$55.27 -0.98 (-1.74%)
As of 12:41 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Sol-Gel Technologies beat analyst earnings expectations but missed on revenue in its Q3 2026 results, released November 12, 2026. The company reported EPS of -$1.72 versus the -$2.07 consensus estimate, while revenue of $41 thousand fell short of the $150 thousand estimate by $109.00 thousand.

Earnings Announcement Details

Quarter
Q3 2026
Time
Before Market Opens
Conference Call
12:30 PM ET

Sol-Gel Technologies EPS Results

Actual EPS
-$1.72
Consensus EPS
-$2.07
Beat/Miss
Beat by +$0.35
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

Sol-Gel Technologies Revenue Results

Actual Revenue
$41 thousand
Expected Revenue
$150 thousand
Beat/Miss
Missed by -$109.00 thousand
YoY Revenue Growth
N/A

Earnings Documents

Sol-Gel Technologies Q3 2026 Earnings FAQ

Sol-Gel Technologies (NASDAQ:SLGL) reported earnings of -$1.72 per share for Q3 2026, beating the consensus estimate of -$2.07. The report was announced on Thursday, November 12, 2026.

Sol-Gel Technologies reported revenue of $41 thousand for Q3 2026, against a consensus estimate of $150 thousand.

Sol-Gel Technologies Earnings Headlines

Sol-Gel Technologies (SLGL) Projected to Release Earnings on Thursday
$0. Later: $29.97.
Bill Poulos is giving away his Simple Options Trading For Beginners book through a temporary link. Once that link expires, it returns to its usual price of $29.97. The content stays the same - plain-English lessons and a handful of proven techniques - only the price changes. Waiting means paying for something you could have gotten for free.tc pixel
See More Sol-Gel Technologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sol-Gel Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sol-Gel Technologies and other key companies, straight to your email.

About Sol-Gel Technologies

Sol-Gel Technologies (NASDAQ:SLGL) is an Israel-based dermatology company that develops topical treatments for skin conditions. Its proprietary technology uses silica-based microencapsulation to formulate active ingredients for topical use.

The company’s products include Epsolay, a benzoyl peroxide cream approved in the United States for inflammatory lesions of rosacea, and Twyneo, a topical combination of tretinoin and benzoyl peroxide approved for acne vulgaris.

Sol-Gel has pursued commercialization and licensing opportunities in the United States and other markets. Its business also includes developing additional dermatology treatments using its formulation platform.

View Sol-Gel Technologies Profile